Biping Y. Deng

Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications

Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature.

Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature.

Journal: Frontiers in immunology
Published: June 29, 2026

Baseline immunonutritional status drives CAR T-cell efficacy, survival, and safety in R/R lymphoma: validation of a pre-lymphodepletion PNI threshold.

Baseline immunonutritional status drives CAR T-cell efficacy, survival, and safety in R/R lymphoma: validation of a pre-lymphodepletion PNI threshold.

Journal: Annals of hematology
Published: April 28, 2026

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.

Journal: Frontiers in immunology
Published: March 05, 2026

ASCT, CAR T-cell, or Combined Consolidation for R/R PCNSL in Re-achieved CR: An Inverse Probability of Treatment Weighting-Adjusted Comparative Study.

ASCT, CAR T-cell, or Combined Consolidation for R/R PCNSL in Re-achieved CR: An Inverse Probability of Treatment Weighting-Adjusted Comparative Study.

Journal: Transplantation and cellular therapy
Published: February 25, 2026

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Journal: Hematological oncology
Published: January 14, 2026

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

Journal: The New England journal of medicine
Published: January 14, 2026

Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study.

Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study.

Journal: Frontiers in immunology
Published: November 28, 2025

Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHL.

Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHL.

Journal: Discover oncology
Published: November 25, 2025

Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study.

Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study.

Journal: Blood cancer journal
Published: November 01, 2025

CD19 CAR-T induces complete and durable remission in cold agglutinin syndrome associated relapse and refractory diffuse large B cell lymphoma.

CD19 CAR-T induces complete and durable remission in cold agglutinin syndrome associated relapse and refractory diffuse large B cell lymphoma.

Journal: Leukemia & lymphoma
Published: October 27, 2025

CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier.

CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier.

Journal: Frontiers in medicine
Published: October 24, 2025

Sequential pseudoallogeneic CAR20/22/19 T-cell therapy in patient with diffuse large B-cell lymphoma relapse after allo-HSCT: a case report.

Sequential pseudoallogeneic CAR20/22/19 T-cell therapy in patient with diffuse large B-cell lymphoma relapse after allo-HSCT: a case report.

Journal: Frontiers in immunology
Published: August 17, 2025
Showing 1-12 of 53

Last Updated: 09/26/2026